Total Funding
28
1
Total FundingPost-IPO Equity raised
Growth Score
-4 pts
Heat Score
-10 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
3654619
Apricus Bio (Nasdaq:APRI) is a pharmaceutical company that has an approved product, Vitaros®, for the treatment of ED.
Richard Pascoe: CEOPast Role: King Pharmaceuticals, Senior Vice President
Steve Martin: SVP & CPOPast Role: AmpliPhi Biosciences, SVP & Chief Financial Officer
About the Company
Apricus Bio (Nasdaq:APRI) is a pharmaceutical company that has an approved product, Vitaros®, for the treatment of ED. Vitaros® is approved in Europe and Canada and will be commercialized by Apricus’ marketing partners, which include Abbott Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), and Bracco SpA. Femprox®,
the Company’s product candidate for the treatment of FSAID, has successfully completed a nearly 400-subject proof-of-concept study.
